TOBY Featured on HIMSS TV Discussing Urine-Based Cancer Detection Technology

TOBY CEO Matthew Laskowski was recently featured on HIMSS TV discussing the machine learning and biomarker analysis technology behind TOBY’s urine-based, multi-cancer detection test.

The conversation explores TOBY’s non-invasive approach to identifying molecular signatures associated with cancer and the company’s FDA Breakthrough Device designation in the United States.

Watch the interview: Link 

To learn more, visit Toby.health.

About TOBY, Inc.:

TOBY, inspired by Sherlock Holmes's Bloodhound, is a BioTech startup focused on the early detection of cancer utilizing mass spectrometry and Artificial Intelligence. TOBY has developed a single urine test that detects 10 cancers, representing over 60% of all new cases globally. This test identifies the unique molecular signature of cancer by combining the precision of mass spectrometry, changes in biomarkers (VOCs), and cutting-edge computational algorithms to deliver early, easy, and affordable cancer screening.

SOURCE TOBY, Inc.

Media Contact: [email protected]

Investor Contact: [email protected]